The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
The disappointing Pynnacle trial is set to yield registrational data.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
A single but durable stable disease sends the microcap's stock up 730%.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
